Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate
BERLIN, Germany, April 26, 2021 / B3C newswire / -- ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.
ProBioGen will now advance the development of Asher's lead candidate in immuno-oncology applying its unique transposase technology DirectedLuck™ which greatly accelerates time-to-clinic.
Asher Biotherapeutics, a biotech company located in the San Francisco Bay Area, is developing cis-targeted immunotherapies with a new level of selectivity for the potential treatment of cancer, autoimmune and infectious diseases. Andy Yeung, CTO at Asher Biotherapeutics said: "With cell line development and manufacturing laying the foundation for a successful clinical program, working with an experienced and reliable CDMO partner to navigate the challenges associated with it is of utmost importance. With its long-standing expertise and cutting edge technologies we are convinced to have found the right partner in ProBioGen."
Dr. René Brecht, ProBioGen's Chief Operations Officer added: "We are very excited to work with Asher Biotherapeutics on their lead immunotherapy program. ProBioGen has ample experience with biotherapeutic development and we are proud to support Asher in the advancement of their clinical pipeline."
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.
The combination of ProBioGen's CHO.RiGHT® expression platform and state-of-the-art process development platforms, together with intelligent and innovative product-specific technologies yield biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years, is privately owned, and based in Berlin, Germany.
Keywords: Cell Line; Cell Culture Techniques; Culture Media; Cell Proliferation; Cell Line Development; Cells, Cultured; Transposases, Transgenes; Bioreactors; Biological Products; Productivity; Technology; Commerce; Germany
Published by B3C newswire